WorldUpstart Announces Companies Selected for Fall 2024 U.S. Market Gateway Accelerator
WorldUpstart U.S. Market Gateway Accelerator Companies - Fall 2024
For Immediate Release: Philadelphia, PA (9. September, 2024) – WorldUpstart proudly announces the launch of its Fall 2024 U.S. Market Gateway Accelerator, featuring nine innovative Life Science and MedTech companies poised for significant growth. This 8-week hybrid program, commencing online on September 9, 2024, culminates in a high-impact visit to Philadelphia from October 28-30, 2024.
This year's participants were selected from a competitive pool of over 100 applicants, including startups and established companies specializing in Drug Development, Medical Devices, and Digital Health from around the globe. The chosen companies, representing France, Israel, Italy, Poland, South Korea, and Switzerland, are set to embark on a journey to expand into the dynamic U.S. market. Through WorldUpstart's intensive accelerator program, these companies will gain valuable insights, mentorship, and access to strategic networks, providing them with the tools and support needed for a successful market entry.
“Expanding into the U.S. market presents immense opportunities, but for foreign companies, navigating this landscape can be challenging and fraught with unknowns," said Karina Sotnik, Founder and CEO of WorldUpstart. "Our soft-landing program, enriched by advice from top experts and trusted industry veterans, provides a tailored strategic roadmap to not only enter the U.S. market but also scale successfully across it."
Meet the Fall 2024 Cohort
Advancing the early detection of cardiac diseases, EFM developed Mudisocard, a telemedical device enabling the immediate diagnosis of critical heart conditions.
Kurage created Neuroskin, an AI-powered neuromuscular electrostimulation device transforming neuromotor rehabilitation by restoring lost functions in patients’ central nervous systems.
Optimizing epilepsy and brain tumor diagnosis, MAG4Health offers a compact MEG device for non-invasive brain defect detection and improving brain health.
MedLea is an AI-driven healthcare platform featuring digital twin technology for predictive lung health, offering personalized medicine solutions for cardiorespiratory disorders.
MUNE is dedicated to enhancing healthcare safety through innovative solutions, such as its Automatic Needle Destroyer (ANDY), which eliminates needlestick injuries, and LABline, a patient blood management solution.
MYNERVA developed innovative AI-driven non-invasive neurostimulation devices designed to alleviate chronic pain and restore the sense of touch in patients with diabetic neuropathy.
Neshima Medical is an innovator in respiratory treatments using its patented liquid-foam therapy (LiFT™) to deliver high doses of therapeutics through the lungs. This approach targets conditions like severe pneumnia, asthma, COPD, IPF, and CF, aiming to reduce mortality rates and hospitalization days.
Vivid Mind Health specializes in the early detection of dementia through its AI-driven product, Memeo, using patented Sound Objects technology to analyze subtle speech nuances, enhancing the accuracy of diagnosing neurodegenerative diseases.
Wide Therapy offers a digital therapy platform tailored to children with special needs, delivering customized simulations and treatment plans to help them overcome personal challenges and achieve functional independence.
About WorldUpstart
WorldUpstart is committed to supporting international companies in Life Science, MedTech, and Digital Health sectors as they prepare to enter the U.S. market. The U.S. Market Gateway Accelerator is designed to help companies overcome market entry challenges, develop strategic expansion roadmaps, and connect with key players, partners, and investors. Over the past three years, the program has graduated 65 companies from 18 countries, with 27 now established in the U.S. and eight achieving FDA approval for their products and services.
With only 20% of international companies typically succeeding in their initial entry into the U.S. market, WorldUpstart's accelerator program more than doubles that success rate to 40%, creating a paradigm shift in how these companies approach U.S. market entry.
